Results 151 to 160 of about 278,336 (309)

Association of Urinary pH With Overall Survival in Patients With Stage IV Cancer: A Single‐Center Retrospective Cohort Study

Cancer Nexus, EarlyView.
ABSTRACT Objective This single‐center retrospective cohort study evaluated whether, among patients with stage IV cancer who participated in a pragmatic “alkalization therapy”—defined as a low potential renal acid load diet plus oral sodium bicarbonate and/or potassium/sodium citrate—urinary pH was associated with long‐term survival.
Shion Kachi, Kazuyuki Suzuki, Reo Hamaguchi, Ryoko Narui, Hiromasa Morikawa, Hiromi Wada   +5 more
wiley   +1 more source

Synergistic effects and clinical utilization of radioimmunotherapy for brain metastases from driver mutation-negative non-small cell lung cancer. [PDF]

Precis Radiat Oncol
This review summarizes how combining radiotherapy with immune checkpoint inhibitors overcomes the immunosuppressive brain microenvironment in non‐small cell lung cancer (NSCLC) brain metastases. The synergy enhances immune cell infiltration and systemic anti‐tumor activity, improving survival outcomes for patients.
Yu S, Ni J, Chen H, Weng N, Yang X, Chu X, Chu L, Zhu Z.   +7 more
europepmc   +2 more sources

Maternal and Neonatal Complications Associated with Breast Cancer Systemic Treatments—A VigiBase Disproportionality Analysis Study

Clinical Pharmacology &Therapeutics, EarlyView.
Pregnancy‐associated breast cancer (PrBC) presents therapeutic challenges. Understanding maternal–fetal safety of systemic anticancer therapies is critical. We performed a case/non‐case disproportionality analysis using the WHO global pharmacovigilance database up to January 2024, to evaluate maternal–fetal outcomes associated with breast cancer (BC ...
Rayan Kabirian, Floriane Jochum, Elise Dumas, Florence Coussy, Kevin Bihan, Bénédicte Lebrun‐Vignes, Barbara Pistilli, Marc‐Antoine Benderra, Lise Selleret, Laurent Chouchana, Fabien Reyal, Anne‐Sophie Hamy, Paul Gougis   +12 more
wiley   +1 more source

Cost-Effectiveness Analysis Of EGFR Mutation Testing And Afatinib Versus Gemcitabine-Cisplatin As First-Line Therapy For Advanced Non-Small-Cell Lung Cancer In China

Cancer Management and Research, 2019
Ruxu You,1,* Jinyu Liu,2,* David Bin-Chia Wu,3 XinYu Qian,4 Boxiang Lyu,5 Yu Zhang,1 Nan Luo4 1Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, People’s Republic of China ...
You R, Liu J, Wu DBC, Qian X, Lyu B, Zhang Y, Luo N   +6 more
doaj  

Population Pharmacokinetics and Exposure‐Response Analyses to Support Cofetuzumab Pelidotin (ABBV‐647) Dose Optimization in Non‐Small Cell Lung Cancer Patients

Clinical Pharmacology &Therapeutics, EarlyView.
Cofetuzumab pelidotin (Cofe‐P) is an anti‐protein tyrosine kinase 7 (PTK7) antibody‐drug conjugate (ADC) being investigated for the treatment of adults with PTK7‐expressing, recurrent non‐small cell lung cancer (NSCLC). The first‐in‐human (FIH) trial demonstrated tolerability of dosages ≤ 2.8 mg/kg once every 3 weeks (Q3W) and ≤ 3.2 mg/kg Q2W ...
Carla Biesdorf, Melanie Rinas, Benjamin Engelhardt, Rabih Saab, Cen Guo, Cristiano Ferlini, Kevin J. Freise, Rajeev M. Menon, Akshanth R. Polepally   +8 more
wiley   +1 more source

Toward Fit‐for‐Purpose Data for Drug Assessment in Non‐small Cell Lung Cancer: A Core Dataset

Clinical Pharmacology &Therapeutics, EarlyView.
Considering the high unmet medical need in people with non‐small cell lung cancer (NSCLC), the drug assessment for targeted therapies often rely on small populations and single‐arm trials, challenging the evaluation by regulatory authorities, health technology assessment bodies (HTAb), and clinicians.
Geeske F. Grit, Maaike van Dartel, Laura Rodwell, Hanneke van der Woude, Cornelis Boersma, Peter G. M. Mol, Doranne Hilarius   +6 more
wiley   +1 more source

First‐Line Osimertinib in Patients with EGFR‐Mutant Advanced Non‐Small Cell Lung Cancer: Outcome and Safety in the Real World: FLOWER Study

The Oncologist, EarlyView., 2021
Abstract Lessons Learned Osimertinib has confirmed effectiveness in this real‐world population of patients with EGFR‐mutant advanced non‐small cell lung cancer. Thromboembolic events occur more frequently than previously reported, suggesting a thrombotic diathesis that requires further investigation. Patients with at least three metastatic sites, brain
Martina Lorenzi, Alessandra Ferro, Fabiana Cecere, Daniela Scattolin, Alessandro Del Conte, Alessandro Follador, Sara Pilotto, Valentina Polo, Mariacarmela Santarpia, Rita Chiari, Alberto Pavan, Alessandro Dal Maso, Valentina Da Ros, Giada Targato, Sabrina Vari, Stefano Indraccolo, Fiorella Calabrese, Stefano Frega, Laura Bonanno, Pier Franco Conte, Valentina Guarneri, Giulia Pasello   +21 more
wiley   +1 more source

Patient‐Reported Outcomes with Selpercatinib Among Patients with RET Fusion–Positive Non‐Small Cell Lung Cancer in the Phase I/II LIBRETTO‐001 Trial

The Oncologist, EarlyView., 2021
Abstract Background LIBRETTO‐001 is an ongoing, global, open‐label, phase I/II study of selpercatinib in patients with advanced or metastatic solid tumors. We report interim patient‐reported outcomes in patients with RET fusion–positive non‐small cell lung cancer (NSCLC).
Anna Minchom, Aaron C. Tan, Erminia Massarelli, Vivek Subbiah, Valentina Boni, Bruce Robinson, Lori J. Wirth, Lisa M. Hess, Min‐Hua Jen, Jennifer Kherani, Elizabeth Olek, Caroline E. McCoach   +11 more
wiley   +1 more source

Model‐based clinical pharmacology profiling of subcutaneous nivolumab in renal cell carcinoma: Bridging to alternative dosing regimens and indications

Clinical Pharmacology &Therapeutics, EarlyView.
A novel model‐informed drug development (MIDD) approach was employed to derive the coprimary endpoints (time‐averaged serum concentration over 28 days [Cavgd28] and minimum serum concentration at steady state [Cminss]) of the phase III CheckMate 67T study (NCT04810078).
Yue Zhao, Zheyi Hu, Elizabeth Gibson, Li Zhu, Heather Vezina, Anna G. Kondic   +5 more
wiley   +1 more source

Correction to: HLA Class II molecule HLA-DRA identifies immuno-hot tumors and predicts the therapeutic response to anti-PD-1 immunotherapy in NSCLC. [PDF]

BMC Cancer
Mei J, Jiang G, Chen Y, Xu Y, Wan Y, Chen R, Liu F, Mao W, Zheng M, Xu J.   +9 more
europepmc   +1 more source